ASH 2020 | Design of a Phase I trial of allogeneic anti-CD123 CAR T-cells in R/R AML
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the design of a Phase I trial (NCT03190278) of allogeneic CAR T-cells in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). UCART123 is a novel allogeneic CAR T-cell product that targets CD123 on the surface of AML cells and is genetically modified in the TCR alpha constant gene to reduce graft versus host disease (GvHD). Pre-clinical studies have shown promising efficacy and preferential AML blast targeting. The trial will follow a modified toxicity probability interval design to assess the safety, tolerability, and activity of UCART123. To date, dose level 1 has caused no dose-limiting toxicities, and enrollment at a higher dose has begun. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Naveen Pemmaraju, MD, has received research funding or grant support from Samus Therapeutics, Cellectis, Stemline Therapeutics, AbbVie, Plexxikon, LFB Biotechnologies, Novartis, SagerStrong Foundation, Affymetrix and Daiichi Sankyo; has received honoraria from Roche Diagnostics, Celgene, Stemline Therapeutics, DAVA Oncology, AbbVie, Incyte Corporation, Blueprint Medicines, Novaritis and MustangBio; and has done consultancy work for Pacylex Pharmaceuticals.
